JP2010506953A5 - - Google Patents

Download PDF

Info

Publication number
JP2010506953A5
JP2010506953A5 JP2009533511A JP2009533511A JP2010506953A5 JP 2010506953 A5 JP2010506953 A5 JP 2010506953A5 JP 2009533511 A JP2009533511 A JP 2009533511A JP 2009533511 A JP2009533511 A JP 2009533511A JP 2010506953 A5 JP2010506953 A5 JP 2010506953A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
pharmaceutical composition
acceptable carrier
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009533511A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010506953A (ja
JP5343267B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/081685 external-priority patent/WO2008049027A1/en
Publication of JP2010506953A publication Critical patent/JP2010506953A/ja
Publication of JP2010506953A5 publication Critical patent/JP2010506953A5/ja
Application granted granted Critical
Publication of JP5343267B2 publication Critical patent/JP5343267B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009533511A 2006-10-17 2007-10-17 タラロゾール代謝物 Expired - Fee Related JP5343267B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85198906P 2006-10-17 2006-10-17
US60/851,989 2006-10-17
PCT/US2007/081685 WO2008049027A1 (en) 2006-10-17 2007-10-17 Talarazole metabolites

Publications (3)

Publication Number Publication Date
JP2010506953A JP2010506953A (ja) 2010-03-04
JP2010506953A5 true JP2010506953A5 (enExample) 2010-09-16
JP5343267B2 JP5343267B2 (ja) 2013-11-13

Family

ID=39314359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533511A Expired - Fee Related JP5343267B2 (ja) 2006-10-17 2007-10-17 タラロゾール代謝物

Country Status (10)

Country Link
US (2) US8188124B2 (enExample)
EP (1) EP2114895A4 (enExample)
JP (1) JP5343267B2 (enExample)
KR (1) KR101419965B1 (enExample)
CN (1) CN101611016B (enExample)
AU (1) AU2007311026B2 (enExample)
BR (1) BRPI0718310A2 (enExample)
CA (1) CA2667053C (enExample)
MX (1) MX2009004096A (enExample)
WO (1) WO2008049027A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
DK2185693T3 (da) 2007-07-31 2019-09-23 Lifescan Inc Differentiering af humane embryoniske stamceller
CA2954431C (en) 2007-11-27 2021-08-24 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic cells
JP5733986B2 (ja) 2008-02-21 2015-06-10 ヤンセン バイオテツク,インコーポレーテツド 細胞の付着、培養、及び剥離のための方法、表面改質されたプレート、並びに組成物
EP2942392B1 (en) 2008-06-30 2018-10-03 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US9234178B2 (en) 2008-10-31 2016-01-12 Janssen Biotech, Inc. Differentiation of human pluripotent stem cells
EP2350265B1 (en) 2008-10-31 2019-04-17 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
KR101774546B1 (ko) 2008-11-20 2017-09-04 얀센 바이오테크 인코포레이티드 마이크로-캐리어 상의 만능 줄기 세포 배양
KR101687344B1 (ko) 2008-11-20 2016-12-16 얀센 바이오테크 인코포레이티드 평면 기재상의 세포 부착 및 배양을 위한 방법 및 조성물
CN102482643B (zh) 2009-07-20 2016-06-29 詹森生物科技公司 人胚胎干细胞的分化
SG10201408552YA (en) 2009-12-23 2015-02-27 Janssen Biotech Inc Differentiation of human embryonic stem cells
PH12012501686A1 (en) 2010-03-01 2020-10-19 Janssen Biotech Inc Methods for purifying cells derived from pluripotent stem cells
RU2587634C2 (ru) 2010-05-12 2016-06-20 Янссен Байотек, Инк. Дифференцирование эмбриональных стволовых клеток человека
EP3372672A1 (en) 2010-08-31 2018-09-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
CN103154237B (zh) 2010-08-31 2016-03-16 詹森生物科技公司 多能干细胞的分化
PL2853589T3 (pl) 2010-08-31 2018-05-30 Janssen Biotech, Inc Różnicowanie ludzkich zarodkowych komórek macierzystych
US9248120B2 (en) 2011-08-23 2016-02-02 The Board Of Trustees Of The Leland Stanford Junior University Reversing intestinal inflammation by inhibiting retinoic acid metabolism
FI2794857T3 (fi) 2011-12-22 2026-03-25 Janssen Biotech Inc Ihmisen alkion kantasolujen erilaistaminen yksittäisiksi hormonaalisiksi insuliinipositiivisiksi soluiksi
CA2866590A1 (en) 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
EP3450544A1 (en) 2012-06-08 2019-03-06 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endodrine cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
BR112015015714A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc suspensão e aglomeração de células pluripotentes humanas para diferenciação em célu-las endócrinas pancreáticas
ES2837763T3 (es) 2012-12-31 2021-07-01 Janssen Biotech Inc Cultivo de células madre embrionarias humanas en la interconexión aire-líquido para la diferenciación en células endocrinas pancreáticas
DK2938723T3 (da) 2012-12-31 2023-02-20 Janssen Biotech Inc Differentiering af humane embryonale stamceller til pancreatiske endokrine celler under anvendelse af hb9-regulatorer
WO2015175307A1 (en) 2014-05-16 2015-11-19 Janssen Biotech, Inc. Use of small molecules to enhance mafa expression in pancreatic endocrine cells
US10420803B2 (en) 2016-04-14 2019-09-24 Janssen Biotech, Inc. Differentiation of pluripotent stem cells to intestinal midgut endoderm cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1102593C (zh) * 1996-06-27 2003-03-05 詹森药业有限公司 N-[4-(杂芳基甲基)苯基]-杂芳基胺类化合物
AP869A (en) 1998-01-05 2000-09-04 Pfizer 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.
IL162533A0 (en) 2001-12-19 2005-11-20 Atherogenics Inc Chalcone derivatives and their use to treat diseases
US20060205945A1 (en) 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
PL372356A1 (pl) 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods

Similar Documents

Publication Publication Date Title
JP2010506953A5 (enExample)
US20260115159A1 (en) Alkylamido compounds and uses thereof
JP2009519993A5 (enExample)
JP2011518833A5 (enExample)
RU2007119380A (ru) Косметические продукты, предназначенные для ухода за собой, включающие соли дигидроксипропилтри (c1-c3алкил) аммония
JP2009502743A5 (enExample)
JP2010530373A5 (enExample)
JP2013515006A5 (enExample)
JP2007511546A5 (enExample)
JP2010506953A (ja) タラロゾール代謝物
JP2012144574A5 (enExample)
JP2009543799A5 (enExample)
JP2007302689A5 (enExample)
JP2007515465A5 (enExample)
CA2595544A1 (en) Compounds having analgesic and/or immunostimulant activity
JP2006515613A5 (enExample)
EP2308828A3 (en) CaSR antagonist
JP2011046708A5 (enExample)
BRPI0518647A2 (pt) processo para a produÇço de um composto, e, composto
JP2018145180A5 (enExample)
JP2007502832A5 (enExample)
EA022994B1 (ru) Способ подавления толерантности к опиоидному анальгетику
JP2004502684A5 (enExample)
JP2010209099A5 (enExample)
JP2013522207A5 (enExample)